These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 2164695)
21. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Holm C; Covey JM; Kerrigan D; Pommier Y Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254 [TBL] [Abstract][Full Text] [Related]
22. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs. Potter AJ; Rabinovitch PS Mutat Res; 2005 May; 572(1-2):27-44. PubMed ID: 15790488 [TBL] [Abstract][Full Text] [Related]
23. Quantitative adaptation of the bacteriophage P4 DNA unknotting assay for use in the biochemical and pharmacological characterization of topoisomerase II. Hofmann GA; Mirabelli CK; Drake FH Anticancer Drug Des; 1990 Aug; 5(3):273-82. PubMed ID: 2169250 [TBL] [Abstract][Full Text] [Related]
24. Lack of effects of ciprofloxacin and the topoisomerase II inhibitors, m-AMSA and nalidixic acid, on DNA repair in cultured rat liver cells. Rosen JE; Schluter G; Williams GM Toxicol Appl Pharmacol; 1996 Oct; 140(2):254-63. PubMed ID: 8887441 [TBL] [Abstract][Full Text] [Related]
25. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine. Sorensen M; Sehested M; Jensen PB Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525 [TBL] [Abstract][Full Text] [Related]
26. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs. Haldane A; Finlay GJ; Baguley BC Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750 [TBL] [Abstract][Full Text] [Related]
27. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Nitiss JL; Liu YX; Hsiung Y Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128 [TBL] [Abstract][Full Text] [Related]
28. Repair of potentially lethal and sublethal radiation damage in x-irradiated ascites tumor cells. Tsuboi A; Okamoto M; Tsuchiya T Jpn J Cancer Res; 1985 Nov; 76(11):1043-8. PubMed ID: 3936825 [TBL] [Abstract][Full Text] [Related]
29. Multiple components of split-dose repair in plateau-phase mammalian cells: a new challenge for phenomenological modelers. Nelson JM; Braby LA; Metting NF; Roesch WC Radiat Res; 1990 Feb; 121(2):154-60. PubMed ID: 2305032 [TBL] [Abstract][Full Text] [Related]
30. Cell cycle dependence of sister chromatid exchange induction by DNA topoisomerase II inhibitors in Chinese hamster V79 cells. Dillehay LE; Denstman SC; Williams JR Cancer Res; 1987 Jan; 47(1):206-9. PubMed ID: 3024815 [TBL] [Abstract][Full Text] [Related]
31. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II. Baloch Z; Cohen S; Coffman FD J Immunol; 1990 Nov; 145(9):2908-13. PubMed ID: 2170526 [TBL] [Abstract][Full Text] [Related]
32. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148 [TBL] [Abstract][Full Text] [Related]
33. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Kamesaki S; Kamesaki H; Jorgensen TJ; Tanizawa A; Pommier Y; Cossman J Cancer Res; 1993 Sep; 53(18):4251-6. PubMed ID: 8395979 [TBL] [Abstract][Full Text] [Related]
34. Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. Ferguson LR; Whiteside G; Holdaway KM; Baguley BC Environ Mol Mutagen; 1996; 27(4):255-62. PubMed ID: 8665870 [TBL] [Abstract][Full Text] [Related]
35. Bleomycin-induced potentially lethal damage and its repair. Utsumi H; Elkind MM Radiat Res; 1989 Sep; 119(3):534-41. PubMed ID: 2475879 [TBL] [Abstract][Full Text] [Related]
36. A novel use for the comet assay: detection of topoisomerase II inhibitors. Salti GI; Das Gupta TK; Constantinou AI Anticancer Res; 2000; 20(5A):3189-93. PubMed ID: 11062742 [TBL] [Abstract][Full Text] [Related]
37. Dependence of mammalian DNA synthesis on DNA supercoiling. III. Characterization of the inhibition of replicative and repair-type DNA synthesis by novobiocin and nalidixic acid. Mattern MR; Scudiero DA Biochim Biophys Acta; 1981 Apr; 653(2):248-58. PubMed ID: 6261824 [TBL] [Abstract][Full Text] [Related]
38. The use of metabolic inhibitors in the analysis of eukaryotic DNA repair. Collins A; Macintyre F; Gedik C Acta Biol Hung; 1990; 41(1-3):65-75. PubMed ID: 2094131 [TBL] [Abstract][Full Text] [Related]
39. Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells. Gedik CM; Collins AR Nucleic Acids Res; 1990 Feb; 18(4):1007-13. PubMed ID: 2156221 [TBL] [Abstract][Full Text] [Related]
40. Action of etoposide (VP-16-123) on human cells: no evidence for topoisomerase II involvement in excision repair of u.v.-induced DNA damage, nor for mitochondrial hypersensitivity in ataxia telangiectasia. Downes CS; Mullinger AM; Johnson RT Carcinogenesis; 1987 Nov; 8(11):1613-8. PubMed ID: 2822276 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]